Kidney Cancer

Among patients with renal cell carcinoma, those on hemodialysis have a 5 times higher risk of dying from the cancer than those not on dialysis, a study found.

In a real-world study, cytoreductive nephrectomy (CN) prior to treatment with tyrosine kinase inhibitors did not improve survival for CN recipients overall, but did improve cancer-specific and progression-free survival in certain subgroups.

In a study involving stage 3 RCC patients, those with positive lymph nodes had markedly inferior 5-year survival compared with those with lymph-node negative disease and 5-year survival similar to those with stage 4 RCC.

In a study of T2 to T3 RCC patients, lymph node dissection did not significantly improve overall survival.

Among patients who undergo treatment for T1a renal cell carcinoma, 5- and 10-year cancer-specific mortality rates rise with age across treatment modalities, a study found.

Active surveillance for small renal masses in older patients offers long-term oncologic efficacy similar to that of partial or radical nephrectomy.

Separate studies demonstrated that partial nephrectomy could be an acceptable alternative to radical nephrectomy in selected cases of high-risk kidney cancer and large renal masses.

Median overall survival (OS) times for the young, intermediate, and elderly groups were 20.0, 17.3, and 21.0 months, respectively.

Patients who underwent image-guided percutaneous cryoablation of cT1 renal cell carcinoma tumors had an estimated local tumor progression-free survival rate 94.9% at 5 years.